Chiome Bioscience : Supplement Documents for Financial Results Q2 FY12/21

Supplement Documents for Financial Results Q2 FY12/21

Aug 13, 2021

To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs

Chiome Bioscience Inc.

Agenda

１．Overview of Q2 FY12/21 "Financial results"

２．Overview of Q2 FY12/21 "Operation highlights"

Appendix.

Corporate information

Pipeline information

		2
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved.

Overview of

Q2 FY12/21 "Financial results"

Copyright © 2017 Chiome Bioscience Inc. All Rights Reserved.

		3
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved.

Financial results: Profit and Loss

(JPY in millions)

		Q2 FY2020	Q2 FY2021	Increase
		(decrease)
	Net sales	173	384	211
	Drug Discovery &	1	103	101	• Upfront payment of the License
	Agreement with Shanghai Henlius
	Development
				Biotech, Inc. for LIV-2008/2008b
	Drug Discovery	171	281	110	• Growth in business with domestic
	Support				pharmaceutical companies
	COS/SGA	909	800	(108)
	R&D Expense	608	459	(149)	• Decrease in the cost of study drug
	manufacturing and CRO in CBA-1205
					program
	Other costs	300	340	40	• Up in material costs due to increased
					business transactions
	Operating Loss	(735)	(415)	320
	Ordinary Loss	(735)	(409)	326
	Net Loss	(736)	(408)	327

Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved.	4

Financial results: Balance Sheet

			(JPY in millions)
	As of	Dec. 31,	As of Jun. 30,
2020	2021
Current assets	3,248	3,087
（Cash on hand in banks)		2,686	2,301
(Other current assets)		562	786
Non-current assets	246	241
Total assets	3,494	3,328
Current Liabilities	342	427
Non-current liabilities	41	42
Total liabilities		384	469
Total net assets		3,109	2,858
Total liabilities and net assets	3,494	3,328

		5
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved.